Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc
Journal website http://www.jocmr.org

Original Article

Volume 10, Number 6, June 2018, pages 493-498

Sodium-Glucose Cotransporter 2 Inhibitors Reduce Prandial Insulin Doses in Type 2 Diabetic Patients Treated With the Intensive Insulin Therapy

Figures

Figure 1.
Figure 1. Recruitment of patients studied.
Figure 2.
Figure 2. Comparison of prandial insulin doses and blood glucose levels before and after the addition of SGLT2i. Black and white circles indicate values before and after the start of SGLT2i, respectively.*P < 0.1 and **P < 0.05 vs. after the start of SGLT2i.
Figure 3.
Figure 3. Changes in body weight and area under the curve (AUC) of blood glucose levels by the addition of SGLT2i. *P < 0.05.
Figure 4.
Figure 4. Changes in daily total insulin doses, basal insulin doses and daily total prandial insulin doses by the addition of SGLT2i. *P < 0.05.

Tables

Table 1. Clinical and Biochemical Characteristics (Mean ± SD) of Patients at Baseline
 
Age (years)56.1 ± 13.0
Body height (cm)160.4 ± 10.0
Body weight (kg)71.5 ± 15.2
Body mass index (kg/m2)26.1 ± 10.4
Systolic blood pressure (mm Hg)123.3 ± 17.1
Diastolic blood pressure (mm Hg)79.8 ± 10.4
HbA1c (%)12.1 ± 2.9
Aspartate aminotrasferase (U/L)21.8 ± 7.1
Alanine aminotrasferase (U/L)25.9 ± 11.2
γ-glutamyltransferase (U/L)40.6 ± 24.8
Uric acid (mg/dL)5.0 ± 1.3
Creatinine (mg/dL)0.7 ± 0.1
Triglyceride (mg/dL)191.1 ± 106.1
High-density lipoprotein-cholesterol (mg/dL)56.2 ± 30.3
Low-density lipoprotein-cholesterol (mg/dL)93.0 ± 19.6

 

Table 2. Prescribed Anti-Diabetic Drugs in Addition to the Intensive Insulin Therapy
 
Anti-diabetic drugsn
Sodium-glucose cotransporter 2 inhibitors12
Dapagliflozin6
Luseogliflozin6
Metformin9
Pioglitazone3
Dipeptidyl peptidase-4 inhibitors6
Glucagon-like peptide-1 analogues5
a-glucosidase inhibitors3